Sohn Camron, Roberts John, Jean-Jacques Edson, Parrish Richard H
Mercer University School of Medicine, Columbus, Georgia, USA.
Enhanced Recovery Comparative Pharmacotherapy Collaborative, Perioperative Care Practice and Research Network, American College of Clinical Pharmacy, Hermitage, Tennessee, USA.
World J Surg. 2024 Dec;48(12):2831-2842. doi: 10.1002/wjs.12387. Epub 2024 Nov 12.
Evidence-based principles in enhanced recovery programs (ERPs) demonstrate substantial improvement in patient outcomes. Determining which latent variables predict composite outcomes could refine ERP pharmacotherapy recommendations.
Using R, pharmacotherapy data were modeled from an existing dataset of adult elective colorectal surgery patients. Primary composite outcome was absence of surgical site infection, venous thromboembolism, postoperative nausea and vomiting, and other in-hospital postoperative complications (POCs). Secondary composite outcome included no postdischarge POCs, hospital length of stay ≤3 days, and no readmission at 7- or 30-days.
Variables with greater odds of predicting both positive primary and secondary composite outcomes included prehospital oral iron and oral antibiotic use, postoperative sugammadex and neostigmine use, postoperative morphine milligram equivalents (MME) ≤ 50, and IV fluid stop by postoperative day 2. Preoperative scopolamine patch (OR = 0.29 and CI = -0.19-0.77) and perioperative gabapentin (OR = 0.46 and CI = 0.06-0.83) had lesser odds for both primary and secondary composite outcomes. Ketamine nonanesthetic bolus, ondansetron IV use, and in-hospital enoxaparin use had paradoxical lesser primary but greater odds for secondary composite outcomes. Prehospital oral laxative use (OR = 0.61 and CI = 0.18-1.04) and postoperative dual IV antibiotics (OR = 0.52 and CI = 0.10-0.94) had lesser odds for primary, but not secondary, outcome.
To improve the odds for positive composite outcomes, oral iron and antibiotics, sugammadex and neostigmine, lower MME, and early IV fluid cessation could be considered essential core items, whereas postoperative dual IV antibiotics and epidural anesthesia might be avoided. Additional research needs to clarify the impacts of in-hospital enoxaparin, ketamine nonanesthetic bolus, and ondansetron use on composite patient outcomes.
强化康复计划(ERP)中的循证原则显示患者预后有显著改善。确定哪些潜在变量可预测综合预后可能会完善ERP药物治疗建议。
使用R语言,从现有的成年择期结直肠手术患者数据集中对药物治疗数据进行建模。主要综合预后指标为无手术部位感染、静脉血栓栓塞、术后恶心呕吐及其他住院术后并发症(POC)。次要综合预后指标包括出院后无POC、住院时间≤3天以及7天或30天内无再入院。
预测主要和次要综合预后均为阳性的可能性较大的变量包括院前口服铁剂和口服抗生素的使用、术后使用舒更葡糖钠和新斯的明、术后吗啡毫克当量(MME)≤50以及术后第2天停止静脉输液。术前使用东莨菪碱贴片(OR = 0.29,CI = -0.19 - 0.77)和围手术期使用加巴喷丁(OR = 0.46,CI = 0.06 - 0.83)对主要和次要综合预后的可能性较小。氯胺酮非麻醉推注、静脉使用昂丹司琼以及住院期间使用依诺肝素对主要综合预后的可能性较小,但对次要综合预后的可能性较大,情况反常。院前口服泻药的使用(OR = 0.61,CI = 0.18 - 1.04)和术后联合静脉使用抗生素(OR = 0.52,CI = 0.10 - 0.94)对主要预后的可能性较小,但对次要预后并非如此。
为提高综合预后为阳性的可能性,口服铁剂和抗生素、舒更葡糖钠和新斯的明、较低的MME以及早期停止静脉输液可被视为基本核心项目,而术后联合静脉使用抗生素和硬膜外麻醉可能应避免。需要进一步研究以阐明住院期间使用依诺肝素、氯胺酮非麻醉推注和昂丹司琼对患者综合预后的影响。